SAN DIEGO, March 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today confirmed that a recently issued patent (US patent number 7,776,007) which covers the Company's branded migraine treatment, SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System, has been listed in the United States Food and Drug Administration (FDA) Orange Book. The listed patent describes essential elements of the DosePro technology that enable a patient to prepare the product for administration in a few simple steps. This patent is not expected to expire until 2025, eight years after any of the previous listed patents for SUMAVEL DosePro.
Zogenix Announces Extension Of SUMAVEL(R) DosePro(TM) U.S. Patent Protection By Eight Years
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.